Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug ...
Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024Dupixent® global net sales(recorded by Sanofi) increased 27% ...
Genelux Corp. (($GNLX)) announced an update on their ongoing clinical study. Genelux Corp. is currently conducting a Phase 2 clinical study titled ...
Akeso, Inc. (($HK:9926)) announced an update on their ongoing clinical study. Study Overview: Akeso, Inc. is conducting a Phase II study titled An ...
The drug, JSKN003, showed promising early efficacy in colorectal cancer patients in China in a Phase I/II trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback